A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo
NCT ID: NCT03642340
Last Updated: 2018-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2017-05-15
2023-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3 and Extensional Study of Besifovir
NCT01937806
Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
NCT02792088
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
NCT03604016
Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate
NCT04202536
Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria
NCT04264312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient who is first prescribed and administered Besivo.
Exclusion Criteria
* Medium to severe Renal function disorder
* The patient under 19
* The Patient who are taboo with L-Carnitine
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IlDong Pharmaceutical Co Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ildong Ildong
Role: STUDY_DIRECTOR
PV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ahn SangHoon
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID-BSB-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.